Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,066 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ovarian Neoplasm Epithelial Clear all
Completed No phase listed Observational

Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer

NCT00986206
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
Interventions
Biomarker LPA and HE4
Diagnostic Test
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00825201
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, liquid chromatography, mass spectrometry, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 6:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

NCT00910000
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Vorinostat, Carboplatin, Gemcitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

NCT00002600
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2001
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Not applicable Interventional

Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients

NCT00082654
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Testicular Germ Cell Tumor
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

NCT00004065
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 30, 2026, 6:20 PM EDT
Active, not recruiting Phase 1 Interventional

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

Gleevec Study for Patients With Ovarian Cancer

NCT00510653
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Imatinib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

NCT02762981
View directory record Official record
Conditions
Solid Tumors
Interventions
Relacorilant with nab-paclitaxel
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 30, 2026, 6:20 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

NCT07278336
View directory record Official record
Conditions
Ovarian Cancer
Interventions
ABBV-901, Bevacizumab, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Results available

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

NCT01772004
View directory record Official record
Conditions
Solid Tumors
Interventions
Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
53
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer

NCT00019916
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
aldesleukin, p53 peptide vaccine, in vitro-treated peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

NCT00088413
View directory record Official record
Conditions
Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer
Interventions
PANVAC-V, PANVAC-F, Sargramostim (GM-CSF, Leukine)
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 2 Interventional

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

NCT00217568
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
pegfilgrastim, carboplatin, docetaxel
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

NCT00357448
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 30, 2026, 6:20 PM EDT
Terminated Phase 1 Interventional

A Study of SGN-STNV in Advanced Solid Tumors

NCT04665921
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
Interventions
SGN-STNV
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 30, 2026, 6:20 PM EDT
Terminated Phase 1Phase 2 Interventional

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

NCT05500508
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer, DIPG Brain Tumor, Ovary Cancer, Breast Cancer, Papillary Thyroid Cancer, Head and Neck Cancer, Gastric Cancer, Nsclc, Mesotheliomas Pleural, Mesothelioma Peritoneum, Esophageal Cancer, Diffuse Midline Glioma, H3 K27M-Mutant, Endometrial Cancer, Cervical Cancer, Melanoma, Colorectal Cancer, Glioma, Malignant
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Not applicable Interventional

Nonmyeloablative Allogeneic Transplant

NCT01272817
View directory record Official record
Conditions
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Waldenstrom Macroglobulinemia, Breast Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Ovarian Cancer, Thymoma
Interventions
Nonmyeloablative Allogeneic Transplant
Procedure
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 72 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1Phase 2 Interventional

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

NCT00889382
View directory record Official record
Conditions
Ovarian Cancer, Solid Tumors
Interventions
OSI-906, Paclitaxel
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
8
States / cities
Scottsdale, Arizona • Orange, California • Lafayette, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00003548
View directory record Official record
Conditions
Cancer
Interventions
aminocamptothecin colloidal dispersion
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 30, 2026, 6:20 PM EDT
Terminated Phase 2 Interventional

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

NCT01685255
View directory record Official record
Conditions
Ovarian Cancer, Genitourinary (GU) Tumors
Interventions
Epacadostat, tamoxifen
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Oct 30, 2026, 6:20 PM EDT
Recruiting No phase listed Observational

Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer

NCT07764133
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Not listed
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 6:20 PM EDT
Completed Not applicable Interventional

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00079222
View directory record Official record
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 30, 2026, 6:20 PM EDT
Completed No phase listed Observational

Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers

NCT00684801
View directory record Official record
Conditions
Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 30, 2026, 6:20 PM EDT